Global Glycomics/Glycobiology Market Size, Forecast, and Trend Highlights Over 2025-2037
Glycomics/Glycobiology Market size was valued at USD 2.1 billion in 2024 and is projected to reach USD 10.2 billion by the end of 2037, rising at a CAGR of 13.5% during the forecast period, i.e., 2025-2037. In 2025, the industry size of glycomics/glycobiology is estimated at USD 2.3 billion.
The global market is growing exponentially, fueled by its extensive patient pool that is necessitating therapeutics for oncology, immunology, and rare metabolic disorders. For instance, in 2023, the article published by the National Institute of Health states that more than 1.6 million cases of cancer were detected annually in the U.S., with glycan-based biomarkers playing a critical role in the treatment procedure. Meanwhile, on the economic front, the PPI and CPI of glycobiology products rose by 6.4% and 5.1% owing to high costs of raw materials and regulatory compliance. Hence, this patient pool, coupled with the demand for precision medicine, has shaped the market growth across all nations.
The global trade in terms of glycomics and glycobiology is appreciably carried out by emerging nations. In this regard, the WTO in 2024 states that more than 75% of glycan exports are led by the U.S., Germany, China, and Japan. Besides, it is reported that the U.S. imports nearly USD 321 million worth of glycobiology enzymes and reagents mainly from Germany and Switzerland. Furthermore, the investments in research have drawn the interest of key players to invest in efficient formulations, as it reached USD 2.2 billion, thereby uplifting market development.
